{
  "@context": "aku-v2",
  "@type": "treatment",
  "@id": "vasc:hht:epistaxis-management",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:15:00.000Z",
    "updated": "2026-01-07T03:15:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.92,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-disorders",
    "type": "treatment",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "Epistaxis Management in HHT",
    "description": "Management strategies for recurrent epistaxis in hereditary hemorrhagic telangiectasia",
    "key_concepts": [
      {
        "concept": "Conservative Measures",
        "details": "Humidification, nasal lubricants, avoidance of trauma, avoid anticoagulation if possible"
      },
      {
        "concept": "Topical Therapies",
        "details": "Topical antifibrinolytics, estrogen creams, bevacizumab nasal spray"
      },
      {
        "concept": "Procedural Interventions",
        "details": "Laser photocoagulation (KTP, Nd:YAG), argon plasma coagulation, sclerotherapy"
      },
      {
        "concept": "Surgical Options",
        "details": "Septodermoplasty (modified Young's procedure) for severe refractory cases"
      },
      {
        "concept": "Systemic Therapy",
        "details": "Bevacizumab (anti-VEGF) for severe, refractory epistaxis with transfusion dependence"
      }
    ],
    "clinical_significance": "Epistaxis is the most common symptom of HHT affecting quality of life"
  },
  "provenance": {
    "primary_sources": ["Faughnan ME et al. Ann Intern Med 2020"]
  }
}
